Tumour Hypoxia In Cancer Therapy

Learn more about how tumour hypoxia in cancer therapy can affect the patients’ outcome

A low oxygen tumour microenvironment drives disease progression, poor treatment response and reduced patient survival.

Research has shown that tumour hypoxia in cancer therapy can lead to the cancer returning. It also shows us that it may also be resistant to chemotherapy, radiotherapy and immunotherapy.

By understanding the hypoxic status of a tumour, we can have a powerful tool to select patients where modern targeted therapies are more likely to work, thus improving patient outcomes.

This major advance in personalised cancer medicine helps people to direct cancer therapy choices and improve the overall outcome of the patient.

At ManTRa DX we are proud to be a diagnostics development company that originates from the Department of Translational Radiobiology based within the Manchester Cancer Research Centre.

Through this extensive research, we have developed tumour-site specific gene expression signatures to assess hypoxia. With this technology, we can deliver major advances in personalised cancer medicine, and from there, the signatures can be used to make a more informed choice on the types of treatments available.

If you would like to discuss our technology, please register your interest via our contact form.